[go: up one dir, main page]

CY1124368T1 - Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman - Google Patents

Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman

Info

Publication number
CY1124368T1
CY1124368T1 CY20211100510T CY211100510T CY1124368T1 CY 1124368 T1 CY1124368 T1 CY 1124368T1 CY 20211100510 T CY20211100510 T CY 20211100510T CY 211100510 T CY211100510 T CY 211100510T CY 1124368 T1 CY1124368 T1 CY 1124368T1
Authority
CY
Cyprus
Prior art keywords
treatment
methods
angelman syndrome
tonic inhibition
increasing tonic
Prior art date
Application number
CY20211100510T
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics, Inc. filed Critical Ovid Therapeutics, Inc.
Publication of CY1124368T1 publication Critical patent/CY1124368T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Η εφεύρεση αναφέρεται σε μια φαρμακευτική σύνθεση που περιλαμβάνει μια αποτελεσματική ποσότητα 4,5,6,7-τετραϋδροϊσοξαζολο(5,4-c)πυριδιν-3-όλης (ΤΗ IP) ή ένα φαρμακευτικώς αποτελεσματικό άλας αυτής και έναν φαρμακευτικά αποδεκτό φορέα ή έκδοχο για χρήση σε μια μέθοδο θεραπείας ενός ανθρώπινου υποκειμένου με σύνδρομο Angelman.
CY20211100510T 2014-06-06 2021-06-10 Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman CY1124368T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia
EP15803364.7A EP3151832B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (1)

Publication Number Publication Date
CY1124368T1 true CY1124368T1 (el) 2022-07-22

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20211100510T CY1124368T1 (el) 2014-06-06 2021-06-10 Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CY20211100509T CY1124366T1 (el) 2014-06-06 2021-06-10 Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100509T CY1124366T1 (el) 2014-06-06 2021-06-10 Μεθοδοι αυξησης τονικης αναστολης και θεραπειας της δευτερογενους αϋπνιας

Country Status (20)

Country Link
US (11) US20150352085A1 (el)
EP (3) EP3151832B1 (el)
JP (4) JP2017516868A (el)
AR (1) AR100772A1 (el)
AU (4) AU2015269667B2 (el)
CA (1) CA2950845C (el)
CY (2) CY1124368T1 (el)
DK (2) DK3372229T3 (el)
ES (2) ES2876350T3 (el)
HR (2) HRP20210901T1 (el)
HU (2) HUE055155T2 (el)
IL (2) IL249287B (el)
LT (2) LT3151832T (el)
MX (2) MX380868B (el)
PL (2) PL3151832T3 (el)
PT (2) PT3151832T (el)
RS (2) RS62006B1 (el)
SI (2) SI3372229T1 (el)
SM (2) SMT202100340T1 (el)
WO (1) WO2015187851A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3151832T (pt) 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
AU2016295138B2 (en) * 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
WO2020061410A1 (en) * 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
MX2021005992A (es) * 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
JP2022514275A (ja) 2018-12-17 2022-02-10 オービッド・セラピューティクス・インコーポレイテッド 非２４時間型睡眠覚醒障害の処置のためのガボキサドールの使用
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
JP2022540917A (ja) * 2019-07-15 2022-09-20 オービッド・セラピューティクス・インコーポレイテッド 治療的処置のためのガボキサドール含有医薬製剤
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
MXPA06011325A (es) 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
JP5909750B2 (ja) 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
JP2012501301A (ja) * 2008-09-01 2012-01-19 ハー・ルンドベック・アクチエゼルスカベット ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物
PT3151832T (pt) * 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
AU2016295138B2 (en) * 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
JP2017516868A (ja) 2017-06-22
JP2023123442A (ja) 2023-09-05
MX391502B (es) 2025-03-21
US20160228418A1 (en) 2016-08-11
AR100772A1 (es) 2016-11-02
US9339495B2 (en) 2016-05-17
US9744159B2 (en) 2017-08-29
CY1124366T1 (el) 2022-07-22
RS62007B1 (sr) 2021-07-30
MX2016016136A (es) 2017-07-05
MX2020012404A (es) 2022-04-11
US20220016091A1 (en) 2022-01-20
MX380868B (es) 2025-03-12
DK3151832T3 (da) 2021-06-14
WO2015187851A1 (en) 2015-12-10
IL249287B (en) 2021-03-25
PT3372229T (pt) 2021-06-17
JP2020063264A (ja) 2020-04-23
AU2024202604A1 (en) 2024-05-09
LT3151832T (lt) 2021-07-12
PT3151832T (pt) 2021-06-15
PL3372229T3 (pl) 2021-10-04
CA2950845C (en) 2023-04-25
US20170087133A1 (en) 2017-03-30
US20250025448A1 (en) 2025-01-23
ES2875742T3 (es) 2021-11-11
EP3151832A1 (en) 2017-04-12
CA2950845A1 (en) 2015-12-10
JP2021178836A (ja) 2021-11-18
IL268960A (en) 2019-10-31
AU2020217342A1 (en) 2020-08-27
US9801864B2 (en) 2017-10-31
EP3372229A1 (en) 2018-09-12
AU2022200085A1 (en) 2022-02-03
SI3372229T1 (sl) 2021-09-30
PL3151832T3 (pl) 2021-10-25
US20160038469A1 (en) 2016-02-11
AU2015269667B2 (en) 2020-07-30
EP3372229B1 (en) 2021-03-24
US20150352085A1 (en) 2015-12-10
US20230051859A1 (en) 2023-02-16
HRP20210902T1 (hr) 2021-09-17
AU2020217342B2 (en) 2021-10-07
ES2876350T3 (es) 2021-11-12
IL268960B (en) 2021-05-31
HUE055155T2 (hu) 2021-11-29
EP3151832A4 (en) 2018-01-17
EP3151832B1 (en) 2021-03-24
DK3372229T3 (da) 2021-06-14
US20170273956A1 (en) 2017-09-28
LT3372229T (lt) 2021-07-12
US9446028B2 (en) 2016-09-20
SMT202100340T1 (it) 2021-07-12
US11278529B2 (en) 2022-03-22
HUE055400T2 (hu) 2021-11-29
IL249287A0 (en) 2017-02-28
AU2015269667A1 (en) 2016-12-22
RS62006B1 (sr) 2021-07-30
EP3795156A1 (en) 2021-03-24
SMT202100343T1 (it) 2021-07-12
SI3151832T1 (sl) 2021-08-31
US20180015076A1 (en) 2018-01-18
US20170071917A1 (en) 2017-03-16
US20180303805A1 (en) 2018-10-25
HRP20210901T1 (hr) 2021-09-17

Similar Documents

Publication Publication Date Title
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
CY1125058T1 (el) Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201691421A1 (ru) Гетероарилы и их применение
MX373703B (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
MX381994B (es) Inhibidor de janus quinasa.
CY1120607T1 (el) Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
IL261920A (en) Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
MX390051B (es) Antagonistas de ep4.
MX393452B (es) Tratamiento de los trastornos depresivos.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний